Hypertension, antihypertensive drugs, and atherogenesis. Mechanisms and clinical implications
- PMID: 2878982
Hypertension, antihypertensive drugs, and atherogenesis. Mechanisms and clinical implications
Abstract
This paper briefly reviews the current knowledge regarding the effects of hypertension and of antihypertensive drugs on the arterial wall and their possible influence on atherogenesis. The potential clinical implications of the experimental data are discussed, and the following recommendations are made regarding therapy of the hypertensive patient: 1) Management of associated hyperlipoproteinemia, even if mild, would appear to be essential in the hypertensive patient because hypertension does not appear to promote atherosclerosis appreciably when plasma cholesterol levels are low. 2) In the mild hypertensive with diastolic blood pressure from 90-95 mmHg without associated target-organ damage or other major risk factors, treatment of the hypertension should primarily be nonpharmacologic in nature. 3) Hypertensive subjects receiving antihypertensive drugs that can have an adverse effect on plasma lipoproteins should have plasma lipids monitored closely; if unfavorable effects occur, revision of therapy should be considered. 4) Major attempts should be made to reduce other risk factors as well, particularly smoking. 5) Because of inherent difficulties in reversing atherosclerosis, treatment of hypertension and other abnormal risk factors should be instituted early in life before severe disease has developed. Finally, research efforts should intensified to delineate the mechanisms by which hypertension and antihypertensive drugs affect the arterial wall and to develop new approaches for protection against arterial injury.
Similar articles
-
The effects of antihypertensive agents on serum lipids and lipoproteins.Arch Intern Med. 1988 Jun;148(6):1280-8. Arch Intern Med. 1988. PMID: 2897834 Review.
-
ESH-ESC guidelines for the management of hypertension.Herz. 2006 Jun;31(4):331-8. doi: 10.1007/s00059-006-2829-3. Herz. 2006. PMID: 16810473
-
Physiopharmacological approach to mechanical factors of hypertension in the atherosclerotic process.J Hum Hypertens. 1991 Aug;5 Suppl 1:15-21. J Hum Hypertens. 1991. PMID: 1941880 Review.
-
Serum lipoproteins during treatment with antihypertensive drugs.J Cardiovasc Pharmacol. 1993;22 Suppl 6:S98-105. J Cardiovasc Pharmacol. 1993. PMID: 7508069 Review.
-
Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47. doi: 10.1016/j.numecd.2005.04.005. Epub 2005 Oct 20. Nutr Metab Cardiovasc Dis. 2006. PMID: 16487914 Clinical Trial.
Cited by
-
The costs of treatment of hypertension in Switzerland and worldwide.Cardiovasc Drugs Ther. 1989 Dec;3(6):931-3. doi: 10.1007/BF01869584. Cardiovasc Drugs Ther. 1989. PMID: 2577286
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical